Cipmolnu 200 Capsule
Prescription Required
Product introduction
Cipmolnu 200 Capsule is the first oral antiviral medication that helps treat mild to moderate COVID-19 in adults. It prevents the virus from multiplying, thereby reducing viral load and disease severity. The drug received emergency use approval from Indian drug regulatory authorities on December 28, 2021.
Cipmolnu 200 Capsule is used in the treatment of HIV infections
Cipmolnu 200 Capsule is used in the treatment of HIV infections
Uses of Cipmolnu Capsule
- Treatment of Mild to moderate Coronavirus disease (COVID-19)
Benefits of Cipmolnu Capsule
In Treatment of Mild to moderate Coronavirus disease (COVID-19)
Cipmolnu 200 Capsule helps manage mild to moderate Covid-19 symptoms in those individuals who are at a high risk of developing severe Covid-19 disease and do not need oxygen administration. This medicine may help you recover from the infection if diagnosed early before hospitalization. If you think you have come in contact with a person who has been infected with Covid-19, or if you feel any of these symptoms, consult your doctor immediately.
Side effects of Cipmolnu Capsule
Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them
Common side effects of Cipmolnu
- Nausea
- Dizziness
- Diarrhea
How to use Cipmolnu Capsule
Take this medicine in the dose and duration as advised by your doctor. Cipmolnu 200 Capsule may be taken with or without food, but it is better to take it at a fixed time.
How Cipmolnu Capsule works
Cipmolnu 200 Capsule is an antiviral medicine. It works by inhibiting the SARS-CoV-2 virus from replicating. This stops the virus from producing new copies and hence decreases the viral load in the body.
Safety advice
Alcohol
CONSULT YOUR DOCTOR
It is not known whether it is safe to consume alcohol with Cipmolnu 200 Capsule. Please consult your doctor.
Pregnancy
CONSULT YOUR DOCTOR
Cipmolnu 200 Capsule may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
Breast feeding
UNSAFE
Cipmolnu 200 Capsule is unsafe to use during breastfeeding. Data suggests that the drug may cause toxicity to the baby.
Driving
CONSULT YOUR DOCTOR
It is not known whether Cipmolnu 200 Capsule alters the ability to drive. Do not drive if you experience any symptoms that affect your ability to concentrate and react.
Kidney
SAFE IF PRESCRIBED
Cipmolnu 200 Capsule is safe to use in patients with kidney disease. No dose adjustment of Cipmolnu 200 Capsule is recommended.
Liver
SAFE IF PRESCRIBED
Cipmolnu 200 Capsule is safe to use in patients with liver disease. No dose adjustment of Cipmolnu 200 Capsule is recommended.
What if you forget to take Cipmolnu Capsule?
If you miss a dose of Cipmolnu 200 Capsule, please consult your doctor.
All substitutes
For informational purposes only. Consult a doctor before taking any medicines.
Cipmolnu 200 Capsule
₹50.0/Capsule
₹58.9/capsule
31% costlier
Molnudac 200mg Capsule
Zydus Cadila
₹33.23/capsule
26% cheaper
₹40.25/capsule
11% cheaper
₹56.7/capsule
26% costlier
₹46.5/capsule
3% costlier
Quick tips
- Do not give Cipmolnu 200 Capsule to children and adolescents aged less than 18 years.
- Do not stop taking Cipmolnu 200 Capsule without talking to your doctor first, as it will protect you from becoming severely ill from COVID-19.
- Even after the treatment, continue practicing COVID-appropriate behavior such as wearing a mask, social distancing, and frequent handwashing.
- For individuals with conceiving potential, it is advisable to use contraceptive methods while taking Molnupiravir and for 4 days after the last dose of the medicine.
Fact Box
Chemical Class
Cytosine Nucleotides
Habit Forming
No
Therapeutic Class
ANTI INFECTIVES
Action Class
Antiviral (Non-HIV) drugs
Patient concerns
FAQs
Can Cipmolnu 200 Capsule be given to children?
No, Cipmolnu 200 Capsule is not approved for use in children or patients below the age of 18 years as it may interfere with the growth of bones and cartilage.
What is the advantage of using Cipmolnu 200 Capsule?
Cipmolnu 200 Capsule has better patient compliance than some other treatment options available against COVID-19. Unlike other medicines that may need a skilled healthcare professional (a doctor or a nurse) to administer, Cipmolnu 200 Capsule is an oral medicine that can be consumed by mouth in the dosage and schedule prescribed by the doctor.
Are there any serious risks of taking Cipmolnu 200 Capsule?
Yes, there are some serious risks involved with using Cipmolnu 200 Capsule, including its potential to cause birth defects in pregnant women and serious damage to the growth of bones and cartilage (which may cause serious muscle damage). Therefore, Cipmolnu 200 Capsule should be used only if prescribed by a doctor and not used for self-medication.
Is taking Cipmolnu 200 Capsule better than getting vaccinated?
No. There is no comparison between the two, and Cipmolnu 200 Capsule is not a substitute for getting vaccinated. Vaccination is for prevention, while Cipmolnu 200 Capsule is used to treat an existing COVID-19 infection, provided the infection is diagnosed at an early stage.
Who is at a high risk of developing severe COVID-19?
People who are at a high risk of developing severe COVID-19 include those aged above 60 years, who are obese, have comorbid conditions including high blood pressure, diabetes, asthma, other medical conditions related to the lungs, kidneys (like dialysis patients), liver, or those who have a weak immunity (like cancer patients).
Who should not take Cipmolnu 200 Capsule?
Cipmolnu 200 Capsule should not be taken to prevent COVID-19 or treat patients hospitalized due to COVID-19. According to the ongoing clinical trials, patients hospitalized with severe COVID-19 infection have not benefited from taking Cipmolnu 200 Capsule.
Want to share the information?
Disclaimer:
Tata 1mg's sole intention is to ensure that its consumers get information that is expert-reviewed, accurate and trustworthy. However, the information contained herein should NOT be used as a substitute for the advice of a qualified physician. The information provided here is for informational purposes only. This may not cover everything about particular health conditions, lab tests, medicines, all possible side effects, drug interactions, warnings, alerts, etc. Please consult your doctor and discuss all your queries related to any disease or medicine. We intend to support, not replace, the doctor-patient relationship.References
- Molnupiravir [EMC SmPC]. London, UK: Merck Sharp & Dohme (UK) Limited; 2021. [Accessed 05 Jan. 2022] (online) Available from:
- U.S. Food and Drug Administration: Center for Drug Evaluation and Research FDA Briefing Document, Antimicrobial Drugs Advisory Committee Meeting, November 30, 2021. [Accessed 05 Jan. 2022] (online) Available from:
- Cipla receives Emergency Use Authorisation (EUA) to launch oral anti-viral drug Cipmolnu®(Molnupiravir 200mg) in India for treatment of adult patients with COVID-19, with SpO2>93% and with high risk of disease progression including hospitalization or death. Cipla: Press Statement. [Accessed 05 Jan. 2022] (online) Available from:
- Sun Pharma receives DCGI approval for Molxvir® (Molnupiravir) in India. Sun Pharma: Press Release. [Accessed 05 Jan. 2022] (online) Available from:
- Molnupiravir. U.S. Food & Drug Administration Antimicrobial Drugs Advisory Committee November 30, 2021. [Accessed 05 Jan. 2022] (online) Available from:
- EUnetHTA Rolling Collaborative Review (RCR19) Authoring Team. Molnupiravir for the treatment of COVID-19. Diemen (The Netherlands): EUnetHTA; 2020. Report No.: RCR19, v1.0. [Accessed 05 Jan. 2022] (online) Available from:
- Molnupiravir [Package leaflet: Information for the patient]. London, UK: Merck Sharp & Dohme (UK) Limited; 2021. [Accessed 05 Jan. 2022] (online) Available from:
- European Medicines Agency. Assessment Report: Use of molnupiravir for the treatment of COVID-19. [Accessed 05 Jan. 2022] (online) Available from:
- Kabinger F, Stiller C, Schmitzová J, et al. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat Struct Mol Biol. 2021;28(9):740-746. [Accessed 05 Jan. 2022] (online) Available from:
- FDA News Release. Coronavirus (COVID-19) Update: FDA Authorizes Additional Oral Antiviral for Treatment of COVID-19 in Certain Adults. December 23, 2021. [Accessed 6th Jan. 2022] (online) Available from:
Marketer details
Name: Cipla Ltd
Address: Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400013
Country of origin: India
Lab tests offered by us
Related/Popular tests
13 people bought this recentlyMRP
₹2000
Inclusive of all taxes
40.0 capsules in 1 bottle
SOLD OUT
Notify me